EGFR
epidermal growth factor receptor, the group of Erb-b2 receptor tyrosine kinases
Basic information
Region (hg38): 7:55019017-55211628
Previous symbols: [ "ERBB" ]
Links
Phenotypes
GenCC
Source:
- inflammatory skin and bowel disease, neonatal, 2 (Moderate), mode of inheritance: AR
- inflammatory skin and bowel disease, neonatal, 2 (Moderate), mode of inheritance: AR
- lung cancer (Definitive), mode of inheritance: AD
- neonatal inflammatory skin and bowel disease (Supportive), mode of inheritance: AR
- inflammatory skin and bowel disease, neonatal, 2 (Strong), mode of inheritance: AR
- non-small cell lung carcinoma (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Inflammatory skin and bowel disease, neonatal, 2 | AR | Allergy/Immunology/Infectious; Cardiovascular | In Inflammatory skin and bowel disease, neonatal, 2, antiinfectious prophylaxis andearly and aggressive treatment of infections may be beneficial, and individuals may also have cardiovascular manifestations such that surveillance may allow beneficial interventions | Allergy/Immunology/Infectious; Cardiovascular | 10686940; 16258541; 24691054 |
| In familial AML, one family has been reported, in which there was an inherited genomic ERBB rearrangement |
ClinVar
This is a list of variants' phenotypes submitted to
- EGFR-related lung cancer (40 variants)
- Non-small cell lung carcinoma (7 variants)
- Lung adenocarcinoma (3 variants)
- Inflammatory skin and bowel disease, neonatal, 2 (1 variants)
- Tyrosine kinase inhibitor response (1 variants)
- Carcinoma of esophagus (1 variants)
- Lung cancer (1 variants)
- Squamous cell lung carcinoma (1 variants)
- not provided (1 variants)
- Glioblastoma (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the EGFR gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
|---|---|---|---|---|---|---|
| synonymous | 15 | 627 | 19 | 661 | ||
| missense | 1236 | 11 | 1260 | |||
| nonsense | 19 | 24 | ||||
| start loss | 0 | |||||
| frameshift | 20 | 29 | ||||
| inframe indel | 10 | 17 | ||||
| splice donor/acceptor (+/-2bp) | 23 | 27 | ||||
| splice region | 78 | 117 | 3 | 198 | ||
| non coding | 25 | 449 | 76 | 550 | ||
| Total | 49 | 28 | 1302 | 1088 | 101 |
Highest pathogenic variant AF is 0.0000197
Variants in EGFR
This is a list of pathogenic ClinVar variants found in the EGFR region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
| Position | Type | Phenotype | Significance | ClinVar |
|---|---|---|---|---|
| 7-55019062-G-T | Lung cancer | Benign/Likely benign (Jul 07, 2023) | ||
| 7-55019087-A-C | Lung cancer | Benign/Likely benign (Jul 07, 2023) | ||
| 7-55019172-G-A | Lung carcinoma | Likely benign (May 28, 2019) | ||
| 7-55019282-G-A | EGFR-related lung cancer | Uncertain significance (Jan 15, 2021) | ||
| 7-55019284-C-G | EGFR-related lung cancer | Uncertain significance (Aug 22, 2022) | ||
| 7-55019284-C-T | EGFR-related lung cancer | Uncertain significance (Apr 30, 2022) | ||
| 7-55019285-C-T | EGFR-related lung cancer | Uncertain significance (Jul 28, 2023) | ||
| 7-55019286-C-T | EGFR-related lung cancer | Likely benign (Jan 28, 2023) | ||
| 7-55019288-C-A | EGFR-related lung cancer | Uncertain significance (Sep 13, 2022) | ||
| 7-55019288-C-G | EGFR-related lung cancer | Uncertain significance (Jul 17, 2023) | ||
| 7-55019288-C-T | EGFR-related lung cancer | Uncertain significance (Nov 08, 2021) | ||
| 7-55019289-C-T | EGFR-related lung cancer | Likely benign (Aug 16, 2022) | ||
| 7-55019290-G-C | EGFR-related lung cancer | Uncertain significance (Jan 27, 2024) | ||
| 7-55019291-G-A | EGFR-related lung cancer | Uncertain significance (Sep 04, 2021) | ||
| 7-55019291-G-C | EGFR-related lung cancer | Uncertain significance (Jan 03, 2024) | ||
| 7-55019292-G-C | EGFR-related lung cancer | Likely benign (Nov 25, 2023) | ||
| 7-55019293-A-G | EGFR-related lung cancer | Uncertain significance (Jan 28, 2024) | ||
| 7-55019295-G-A | EGFR-related lung cancer | Likely benign (Nov 10, 2023) | ||
| 7-55019295-G-C | EGFR-related lung cancer | Likely benign (Jan 03, 2024) | ||
| 7-55019295-G-T | EGFR-related lung cancer | Likely benign (Jan 17, 2024) | ||
| 7-55019296-G-C | EGFR-related lung cancer • Hereditary cancer-predisposing syndrome • EGFR-related disorder | Uncertain significance (Nov 04, 2023) | ||
| 7-55019297-C-A | EGFR-related lung cancer | Uncertain significance (Apr 26, 2021) | ||
| 7-55019298-C-A | EGFR-related lung cancer | Likely benign (Feb 12, 2022) | ||
| 7-55019298-C-T | EGFR-related lung cancer | Likely benign (Jun 01, 2024) | ||
| 7-55019299-G-A | EGFR-related lung cancer | Uncertain significance (Apr 23, 2023) |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| EGFR | protein_coding | protein_coding | ENST00000275493 | 28 | 237600 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.368 | 0.632 | 125726 | 0 | 22 | 125748 | 0.0000875 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 1.87 | 561 | 701 | 0.801 | 0.0000445 | 8006 |
| Missense in Polyphen | 203 | 324.57 | 0.62544 | 3634 | ||
| Synonymous | -1.65 | 315 | 280 | 1.13 | 0.0000199 | 2270 |
| Loss of Function | 5.83 | 15 | 66.2 | 0.226 | 0.00000373 | 742 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000272 | 0.000271 |
| Ashkenazi Jewish | 0.000198 | 0.000198 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.000106 | 0.000105 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.0000327 | 0.0000327 |
| Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS- RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Plays a role in enhancing learning and memory performance (By similarity). {ECO:0000250|UniProtKB:Q01279, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11602604, ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:15611079, ECO:0000269|PubMed:17115032, ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:27153536, ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:7679104, ECO:0000269|PubMed:8144591, ECO:0000269|PubMed:9419975}.; FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins. {ECO:0000269|PubMed:21516087}.;
- Disease
- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16672372}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Inflammatory skin and bowel disease, neonatal, 2 (NISBD2) [MIM:616069]: A disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized. {ECO:0000269|PubMed:24691054}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);Non-small cell lung cancer - Homo sapiens (human);Gastric cancer - Homo sapiens (human);Focal adhesion - Homo sapiens (human);Relaxin signaling pathway - Homo sapiens (human);Oxytocin signaling pathway - Homo sapiens (human);Central carbon metabolism in cancer - Homo sapiens (human);Choline metabolism in cancer - Homo sapiens (human);Adherens junction - Homo sapiens (human);Melanoma - Homo sapiens (human);Cushing,s syndrome - Homo sapiens (human);Bladder cancer - Homo sapiens (human);HIF-1 signaling pathway - Homo sapiens (human);Jak-STAT signaling pathway - Homo sapiens (human);Endocytosis - Homo sapiens (human);GnRH signaling pathway - Homo sapiens (human);Breast cancer - Homo sapiens (human);ErbB signaling pathway - Homo sapiens (human);Gap junction - Homo sapiens (human);FoxO signaling pathway - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);Epithelial cell signaling in Helicobacter pylori infection - Homo sapiens (human);Hepatocellular carcinoma - Homo sapiens (human);Glioma - Homo sapiens (human);Prostate cancer - Homo sapiens (human);Calcium signaling pathway - Homo sapiens (human);Estrogen signaling pathway - Homo sapiens (human);Rap1 signaling pathway - Homo sapiens (human);Ras signaling pathway - Homo sapiens (human);MAPK signaling pathway - Homo sapiens (human);Phospholipase D signaling pathway - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);MicroRNAs in cancer - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Hepatitis C - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);Pancreatic cancer - Homo sapiens (human);Endometrial cancer - Homo sapiens (human);Colorectal cancer - Homo sapiens (human);EGFR Inhibitor Pathway, Pharmacodynamics;Human papillomavirus infection - Homo sapiens (human);Erlotinib Pathway, Pharmacokinetics;Vemurafenib Pathway, Pharmacodynamics;update your name in edit mode;Phosphatidylinositol Phosphate Metabolism;Joubert syndrome;Panitumumab Action Pathway;Cetuximab Action Pathway;Trastuzumab Action Pathway;Gefitinib Action Pathway;Erlotinib Action Pathway;EGF-Core;JAK-STAT-Core;Androgen receptor signaling pathway;miR-targeted genes in epithelium - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Signaling Pathways in Glioblastoma;AGE-RAGE pathway;Gastric Cancer Network 2;Spinal Cord Injury;Aryl Hydrocarbon Receptor;JAK-STAT;Hair Follicle Development- Induction (Part 1 of 3);Bladder Cancer;TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer;Extracellular vesicle-mediated signaling in recipient cells;Aryl Hydrocarbon Receptor Pathway;Nuclear Receptors Meta-Pathway;Focal Adhesion;Rac1-Pak1-p38-MMP-2 pathway;Photodynamic therapy-induced AP-1 survival signaling.;Association Between Physico-Chemical Features and Toxicity Associated Pathways;MAPK Signaling Pathway;ERK Pathway in Huntington,s Disease;BMP Signaling Pathway in Eyelid Development;ESC Pluripotency Pathways;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;Pathways in clear cell renal cell carcinoma;Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors;Endometrial cancer;PI3K-Akt Signaling Pathway;Ebola Virus Pathway on Host;Ebola Virus Pathway on Host;Ras Signaling;EGF-EGFR Signaling Pathway;Regulation of Actin Cytoskeleton;ErbB Signaling Pathway;SHC1 events in ERBB2 signaling;Developmental Biology;Signaling by PTK6;Signaling by GPCR;RAGE;Disease;Signal Transduction;Gene expression (Transcription);Vesicle-mediated transport;role of egf receptor transactivation by gpcrs in cardiac hypertrophy;egf signaling pathway;trefoil factors initiate mucosal healing;angiotensin ii mediated activation of jnk pathway via pyk2 dependent signaling;mcalpain and friends in cell motility;sprouty regulation of tyrosine kinase signals;cbl mediated ligand-induced downregulation of egf receptors pathway;Membrane Trafficking;role of erbb2 in signal transduction and oncology;keratinocyte differentiation;Generic Transcription Pathway;Prolactin;ERBB2 Activates PTK6 Signaling;map kinase inactivation of smrt corepressor;Alpha6Beta4Integrin;SHC1 events in EGFR signaling;RNA Polymerase II Transcription;PTK6 promotes HIF1A stabilization;NOTCH3 Activation and Transmission of Signal to the Nucleus;EGFR interacts with phospholipase C-gamma;Signaling by NOTCH3;Signaling by NOTCH;AndrogenReceptor;EGFR downregulation;Signaling by EGFR;Downregulation of ERBB2 signaling;IL-7 signaling;Clathrin-mediated endocytosis;EGFR1;SHP2 signaling;agrin in postsynaptic differentiation;ErbB1 downstream signaling;GAB1 signalosome;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;Signaling events mediated by TCPTP;Thromboxane A2 receptor signaling;PIP3 activates AKT signaling;JAK STAT pathway and regulation;GRB2 events in ERBB2 signaling;EGFR Transactivation by Gastrin;E-cadherin signaling in keratinocytes;Signaling by Non-Receptor Tyrosine Kinases;Posttranslational regulation of adherens junction stability and dissassembly;EPO signaling;a6b1 and a6b4 Integrin signaling;Signal transduction by L1;Gastrin;Cargo recognition for clathrin-mediated endocytosis;PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling;Negative regulation of the PI3K/AKT network;Signaling by EGFRvIII in Cancer;Signaling by EGFR in Cancer;L1CAM interactions;EGFR-dependent Endothelin signaling events;Direct p53 effectors;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;GRB2 events in EGFR signaling;Axon guidance;Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors;Leptin;Constitutive Signaling by Aberrant PI3K in Cancer;PI3K events in ERBB2 signaling;PLCG1 events in ERBB2 signaling;Signaling by ERBB2;ERBB2 Regulates Cell Motility;PI3K/AKT Signaling in Cancer;Signaling by ERBB4;TNFalpha;Inhibition of Signaling by Overexpressed EGFR;Signaling by Overexpressed Wild-Type EGFR in Cancer;Constitutive Signaling by EGFRvIII;Signaling by Receptor Tyrosine Kinases;VEGF;Gastrin-CREB signalling pathway via PKC and MAPK;G alpha (q) signalling events;GPCR downstream signalling;Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants;Signaling by Ligand-Responsive EGFR Variants in Cancer;EGF;Intracellular signaling by second messengers;Stabilization and expansion of the E-cadherin adherens junction;LPA receptor mediated events;Diseases of signal transduction;Internalization of ErbB1;Regulation of Telomerase;Arf6 signaling events;Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling;Signaling events mediated by PTP1B;ErbB receptor signaling network;Syndecan-3-mediated signaling events
(Consensus)
Recessive Scores
- pRec
- 0.989
Intolerance Scores
- loftool
- 0.0455
- rvis_EVS
- -2.16
- rvis_percentile_EVS
- 1.44
Haploinsufficiency Scores
- pHI
- 1.00
- hipred
- Y
- hipred_score
- 0.800
- ghis
- 0.654
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.996
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Egfr
- Phenotype
- endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; craniofacial phenotype; muscle phenotype; cellular phenotype; immune system phenotype; homeostasis/metabolism phenotype; liver/biliary system phenotype; respiratory system phenotype; embryo phenotype; neoplasm; pigmentation phenotype; reproductive system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; digestive/alimentary phenotype; renal/urinary system phenotype; skeleton phenotype;
Zebrafish Information Network
- Gene name
- egfra
- Affected structure
- dorsal aorta
- Phenotype tag
- abnormal
- Phenotype quality
- decreased diameter
Gene ontology
- Biological process
- MAPK cascade;activation of MAPKK activity;ossification;embryonic placenta development;positive regulation of protein phosphorylation;hair follicle development;regulation of transcription by RNA polymerase II;translation;response to osmotic stress;signal transduction;cell surface receptor signaling pathway;transmembrane receptor protein tyrosine kinase signaling pathway;epidermal growth factor receptor signaling pathway;activation of phospholipase C activity;salivary gland morphogenesis;midgut development;learning or memory;circadian rhythm;cell population proliferation;positive regulation of cell population proliferation;positive regulation of nitric oxide mediated signal transduction;magnesium ion homeostasis;regulation of phosphatidylinositol 3-kinase signaling;diterpenoid metabolic process;peptidyl-tyrosine phosphorylation;cerebral cortex cell migration;cell differentiation;positive regulation of cell growth;lung development;positive regulation of cell migration;positive regulation of superoxide anion generation;positive regulation of peptidyl-serine phosphorylation;response to cobalamin;response to hydroxyisoflavone;cellular response to reactive oxygen species;peptidyl-tyrosine autophosphorylation;ERBB2 signaling pathway;negative regulation of epidermal growth factor receptor signaling pathway;wound healing;negative regulation of protein catabolic process;positive regulation of phosphorylation;ovulation cycle;hydrogen peroxide metabolic process;activation of phospholipase A2 activity by calcium-mediated signaling;negative regulation of apoptotic process;positive regulation of MAP kinase activity;tongue development;positive regulation of DNA repair;positive regulation of DNA replication;negative regulation of Notch signaling pathway;positive regulation of bone resorption;positive regulation of transcription, DNA-templated;positive regulation of vasoconstriction;negative regulation of mitotic cell cycle;positive regulation of transcription by RNA polymerase II;regulation of JNK cascade;viral entry into host cell;protein autophosphorylation;phosphatidylinositol phosphorylation;astrocyte activation;positive regulation of fibroblast proliferation;digestive tract morphogenesis;positive regulation of smooth muscle cell proliferation;neuron projection morphogenesis;positive regulation of epithelial cell proliferation;positive regulation of inflammatory response;regulation of peptidyl-tyrosine phosphorylation;regulation of nitric-oxide synthase activity;protein insertion into membrane;response to calcium ion;positive regulation of protein kinase B signaling;positive regulation of synaptic transmission, glutamatergic;morphogenesis of an epithelial fold;membrane organization;eyelid development in camera-type eye;response to UV-A;regulation of ERK1 and ERK2 cascade;positive regulation of ERK1 and ERK2 cascade;cellular response to amino acid stimulus;cellular response to mechanical stimulus;cellular response to cadmium ion;cellular response to epidermal growth factor stimulus;cellular response to estradiol stimulus;cellular response to dexamethasone stimulus;positive regulation of canonical Wnt signaling pathway;liver regeneration;positive regulation of blood vessel diameter;cell-cell adhesion;positive regulation of protein kinase C activity;negative regulation of ERBB signaling pathway;positive regulation of NIK/NF-kappaB signaling;positive regulation of prolactin secretion;positive regulation of protein localization to plasma membrane;positive regulation of production of miRNAs involved in gene silencing by miRNA;negative regulation of cardiocyte differentiation;regulation of cell motility
- Cellular component
- Golgi membrane;extracellular space;nucleus;cytoplasm;endosome;endoplasmic reticulum membrane;plasma membrane;integral component of plasma membrane;focal adhesion;basal plasma membrane;cell surface;endosome membrane;membrane;basolateral plasma membrane;apical plasma membrane;endocytic vesicle;clathrin-coated vesicle membrane;early endosome membrane;nuclear membrane;protein-containing complex;receptor complex;membrane raft;synapse;perinuclear region of cytoplasm;Shc-EGFR complex;multivesicular body, internal vesicle lumen
- Molecular function
- virus receptor activity;chromatin binding;double-stranded DNA binding;MAP kinase kinase kinase activity;protein tyrosine kinase activity;transmembrane receptor protein tyrosine kinase activity;transmembrane signaling receptor activity;epidermal growth factor-activated receptor activity;Ras guanyl-nucleotide exchange factor activity;integrin binding;protein binding;calmodulin binding;ATP binding;enzyme binding;protein kinase binding;protein phosphatase binding;nitric-oxide synthase regulator activity;ubiquitin protein ligase binding;identical protein binding;cadherin binding;phosphatidylinositol-4,5-bisphosphate 3-kinase activity;protein heterodimerization activity;epidermal growth factor binding;actin filament binding